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Quality assurance and safety of hematopoietic stem cells (HSC) with special emphasis on bacterial and fungal contamination is the 
prerequisite for any transplantation procedure. The aim was to determine the incidence rate of such contamination during processing 
of transplantation material with regard to HSC source: peripheral blood stem cell (PBSC), bone marrow (BM), or cord blood (CB). Analysis 
involved autologous and allogenic products dedicated for patients and comprised in all 4135 donations, including 112 BM (2.70%), 
3787 PBSC (91.60%), and 236 CB (5.70%) processed in cell bank over the period 1996–2016. Aerobic and anaerobic contamination was 
determined.
Analysis of the 20-year data revealed 42 contaminated products: 25 PBSC (0.66% of tested units) and 17 CB (7.20% of tested units). 
No microbial contamination of BM products was detected. Overall percentage of contaminated products was 1.01%, mostly with 
Staphylococcus epidermidis (61.36%). Bacterial contamination rate at cell bank is relatively low and processing in a closed system does 
not seem as crucial as might be expected. This is particularly true for BM components. Equally important are evaluation of donor’s 
medical status and condition of the puncture site for collection of source material. Implementation of appropriate sample collection 
procedures should help minimize the risk of false-positive results due to environmental contamination.
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Introduction
Quality and safety of hematopoietic stem cells (HSC) is the prerequisite 
of any successful transplantation. Ready-for-use HSC transplantation 
material is the outcome of several preparation steps including the 
following: source material collection, sample collection, centrifugation, 
removal of unwanted plasma and cells, cryopreservation, storage, 
thawing, etc. Each step of stem cells collection and processing is 
burdened with a risk of product contamination – especially bacterial 
– and the overall risk rises with introduction of each additional activity 
[1, 2].
Discussions on the safety of substances of human origin are typically 
focused on viral infections, although bacterial contamination is of 
significance as it occurs more frequently and bacteria are observed to 
have developed resistance [3].
Safeguard against microbial contamination of HSC products is the 
subject of numerous studies which focus attention on bacterial detection 
methods, immediate access to test results, sensitivity of tests, sample 
collection techniques, and the effect of cryoprotectants [4].
It is therefore important for any stem cell bank involved in collection 
and preparation of transplantation material to follow good practice 
guidelines and regulations [5, 6, 7] already in force for several years 
both in European countries and the United States [8]. In many cases, 
HSC processing requires open system which increases the risk of 
bacterial contamination. The risk can be reduced by extending the 
closed system over the entire preparation process. Special kits were 
therefore developed for all activities to be performed within a closed 
system and cryoprotectant pre-filled syringes were used to secure 
sterile connections.
Identification of bacterial contamination especially in autologous 
transplantation material leads to product discard and either shortage of 
such material or higher risk of unsuccessful clinical outcome. For most 
allogeneic transplantations, the infusion of stem cells is performed 
immediately after collection so the risk of bacterial contamination is 
higher because at that moment the microbial status of the HSC product 
is yet unknown (test results become available after several days).
Infections in immunocompromised patients are a particular challenge. 
Apart from HSC donor, infection from another possible source is 
transmission of viral infection from one cryopreserved component to 
another. Certain procedures have been launched to eliminate such 
infection routes which – apart from HSC donor testing – include 
implementation of storage methods that contribute to reduction of 
infection risk [9, 10]. Appropriate procedures of HSC collection and 
processing as well as diagnostic testing are crucial for prevention of 
bacterial contamination.
Up to date observations and literature reports reveal a variety of infections 
that can be transmitted with transplantation material. Diagnosis is 
complicated by factors such as type of bacteria (aerobic/anaerobic), low 
abundance of specimen, or slow bacterial growth. It is therefore essential 
for quality control to provide adequate culture media [11, 12]. Prevention 
of bacterial and fungal contamination is the fundamental task of any cell 
bank processing transplantation material.
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The study aim was to estimate the rate of bacterial and fungal 
contamination during processing of transplantation material in our 
cell bank over a period of 20 years with regard to type of HSC source, 
that is, peripheral blood stem cell (PBSC), bone marrow (BM), or 
umbilical cord blood (CB).
Materials and Methods
We performed an analysis of HSC products dedicated for clinical 
use and processed from PBSC, BM, and CB donations collected 
in the period 1996–2016. PBSC and BM materials were collected 
at the Institute of Hematology and Transfusion Medicine (IHTM), 
whereas CB was obtained from gynecological-obstetrics hospitals. 
All products were processed at the IHTM cell bank. The analysis 
also included allogenic HSC products received from other centers, 
subjected to preparation at IHTM and dedicated for the IHTM patients 
(491 products in the years 2012–2016).
A total of 4135 HSC products were analyzed, including 112 BM 
(2.70%), 3787 PBSC (91.60%), and 236 CB (5.70%), all of which 
were prepared at the IHTM cell bank over the 1996–2016 period. 
Autologous products accounted for 79% of all studied PBSC grafts 
and 66% of BM products.
BM was collected in operating room conditions following puncture-site 
disinfection according to surgical procedures. It was then subjected 
to filtration and further processing with Cobe Spectra (Gambro) and 
Optia (Terumo BCT) cell separators.
PBSCs were collected using CS-3000 (Baxter), Cobe Spectra 
(Gambro), and Optia (Terumo BCT) cell separators with a two-step 
disinfection method of venipuncture site or using vascular catheter.
CB was collected following disinfection with standard agents routinely 
used at gynecological and obstetric wards.
PBSC and BM collected at IHTM were subjected to preparation 
within an hour of collection. Allogenic products from other centers 
were processed within 48 hours of collection.
Once the preparation process was completed and the cryoprotectant 
added, samples were collected for bacteriological testing of BM 
and PBSC destined for long-term storage. Until the end of 2014, 
samples from PBSC and BM components were collected only after 
processing was completed. Since 2015, samples were collected both 
after collection (post-collection samples) and after processing. CB 
samples were collected both before and after processing. The final 
DMSO concentration in the product was 10%.
Each sample was collected approximately 1 hour of collection directly 
from the product. Samples of 1 ml for each culture bottle (aerobic and 
anaerobic) were collected from drain segments and directly inoculated 
in a laminar air flow chamber. Aerobic and anaerobic bacteria were 
tested at room temperature and 35°C using various media. Two (2) 
trypcase-soybean (TSB-T) and one (1) Schaedler + Vit K3 (BioMerieux) 
media were used for PBSC and BM; Bactec Peds Plus/F and Bactec 
Lytic/10/Anaerobic/F (Becton-Dickinson) were used for CB. Samples 
were incubated for 7 days. In the years 1996–2002, PBSC and BM 
samples were inoculated on home-made Trypcase-soybean and on 
Schaedler media in the Laboratory of Microbiology IHTM. Until the end 
of 2014, samples from PBSC and BM components were collected only 
after completion of processing. In 2015, we decided to collect samples 
both after collection (post-collection samples) and after processing.
Until 2012, cell processing was performed mostly within a closed 
system with the exception of BM filtration and preparation of 
a cryoprotectant mixture which took place in a laminar air flow 
chamber. In 2012, a decision was made to replace 5% albumin used 
for preparation of cryoprotectant mixture with plasma and since then 
only the closed system was in use. BM was subjected to filtration 
immediately after collection in operating room conditions.
The laminar air flow chamber was subjected to systematic weekly 
microbiological control; no bacterial contamination was reported.
Results
A total of 42 contaminated products were detected including 25 PBSC 
(0.66% of all tested PBSC units) and 17 CB (7.20% of all tested CB 
units). No contamination was reported for BM components (Tab. I). 
The overall percentage of contaminated components was 1.01%. Until 
the end of 2014, when all samples were collected only in the post-
processing period, 22 contaminations were found. In 2015, two (2) 
contaminated products were determined; 1 sample tested in aerobic 
environment was contaminated with Staphylococcus epidermidis 
and 1 sample from the other product was tested in anaerobic 
environment and found contaminated with Priopionobacterium acnes. 
In 2016, we found one product contaminated with Staphylococcus 
epidermidis – one sample tested in aerobic environment. Eight (8) CB 
samples were found contaminated in the post-collection period and 15 
in the post-processing period. In two samples identified as contaminated 
before processing no bacteria were identified after the processing 
Table I. Number of processed products in consecutive years 
including contaminated products





1996 7 (1) 0 0
1997 27 (1) 0 17
1998 21 2 18 (1)
1999 26 9 55 (6)
2000 54 8 60 (4)
2001 60 4 10
2002 44 10 3
2003 55 6 8
2004 53 5 3
2005 98 3 0
2006 107 (2) 3 0
2007 108 1 0
2008 255 (1) 3 0
2009 288 (2) 10 0
2010 211 (6) 12 0
2011 278 (1) 7 30 (3)
2012 282 (3) 12 32 (3)
2013 348 (1) 12 0
2014 425 (4) 2 0
2015 468 (2) 2 0
2016 572 (1) 1 0
Overall 3787 (25) 112 236 (17)
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was completed. Staphylococcus epidermidis species predominated 
(61.36%). No fungal contamination was observed. Table II presents 
the detected contaminations with regard to the type of component. The 
contamination rate varied during the period under analysis (Fig. 1). 
In 2010, three (3) products were detected as contaminated with 
Staphylococcus epidermidis; all three came from the same patient with 
a vascular catheter and were collected on consecutive days. In another 
patient, two different bacteria species (Staphyloccocus epidermidis 
and Staphyloccocus aureus) were identified on consecutive days. In 
2012, two (2) different bacterial species Enterococcus faecalis and 
Staphyloccocus epidermidis were identified in one product. Products 
collected in other centers were tested on site immediately after collection 
and no contamination was found.
Discussion
Bacteriological control of HSC products dedicated for clinical use is 
an extremely significant pre-condition for successful transplantation. 
Some centers perform transplantations of bacteria-contaminated 
HSC products but patients are supported by antibiotic therapy [1, 2, 
13, 14, 15]. In others, contaminated products are tested for bacterial 
presence also after thawing, which facilitates the patient’s follow-up. 
On the other hand, it has also been determined that cryopreservation 
might reduce the growth capacity of bacteria [16].
IHTM regulations state that any bacteria-contaminated component – 
either autologous or allogenic – is deferred from clinical use. It 
is therefore crucial to make sure that the number of discarded 
components is as low as possible. The testing of samples both after 
collection and after processing is the crucial stage of proper cell 
banking. Such protocol helps to evaluate the quality of performance 
both during collection and processing and may also improve the 
probability of detection of small number of bacteria in product.
Our study results demonstrate that the contamination rate for HSC 
products at IHTM is low as compared to several other centers. 
Literature data report that the contamination rate for all products 
varies from 0.2% to as much as 26.3% [1, 5, 8, 16, 17]. It is even 
higher for CB products; the percentage amounts up to 48% [18]. 
In our study, we also observed that CB contaminations occur more 
frequently than for PBSC and BM. Moreover, in more than 50% of 
infected samples, bacteria were directly detected in the post-collection 
period. The very conditions of CB collection increase the risk of 
bacterial contamination either directly or through kit contamination. 
Processing of CB for clinical use is another challenge due to small 
specimen volume and special sterility requirements. Ongoing studies 
on optimization of CB sampling are focused on dilution of source 
material, determination of the best timing for sample collection, 
collection of test samples from CB remnants, that is, plasma or red 
blood cells [19]. To a lesser degree, this refers to PBSC and BM 
testing mostly because of larger volume of product. It should be kept 
in mind, however, that each sample collection reduces the amount of 
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Fig. 1. Frequency of bacterial contamination in HCS products in relations to HSC source in 1996-2016 years
Fig. 1. Frequency of bacterial contamination in HCS products in relations to HSC source in years 1996–2016
Table II. Microorganisms identified in PBSC and CB products in 
years 1996–2016
Microorganism No. of contaminated products
PBSC CB
Staphyloccocus epidermidis 19 8
Priopionobacterium acnes 2 -
Streptococcus agalactiae - 2
Escherichia coli - 2
Staphyloccocus aureus 1 -
Enterococcus faecalis 1 1
Staphyloccocus cohni 1 -
Staphylococcus vitulinus 1 -
Brevibacterium spp. 1 -
Dermabacter hominis - 1
Leuconostoc spp. - 1
Staphylococcus capitis - 1
Micrococcus spp. - 1
Streptococcus sanguinis - 1
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Surprisingly, no bacterial contaminations were found in BM 
components, although collection and processing procedures were 
performed in open system. It would seem that BM components are 
more exposed to bacterial contamination because of the type and 
conditions of activities performed as well as the large specimen 
volume. In other centers, BM was typically contaminated directly after 
collection as well as during processing [11, 13, 20, 21].
The most common contamination reported for HSC products is with 
human skin bacteria. This is also confirmed by our study where 
Staphylococcus epidermidis was detected in 61.36% of all collected 
samples [17, 21, 22]. Microorganisms found in BM products differed 
from those in PBSC products. In his study, Vanneaux et al. [20] 
also identified Priopionobacterium acnes as the most common 
microorganism beside coagulase-negative Staphylococcus. In the 
study of Kozłowska-Skrzypczak et al. [23], however, the most common 
microbial contamination detected in both PBSC and in BM was with 
Bacillus species although in this cell bank the preparation procedure 
was performed in a closed system exclusively. The same bacterial 
species was detected in laminar flow chamber where test samples 
were collected. In our cell bank where test samples are collected once 
a week, no bacteria were found in laminar flow.
The case of one patient (all products contaminated) revealed the source 
of contamination to be neither the processing nor sampling technique 
but the tip of the catheter used for cell collection. It is therefore crucial 
to make sure the collection procedure does not affect component 
sterility even before the HSC collection begins. Cell collection should 
be undertaken after a thorough check of the vascular catheter; patients 
at risk of asymptomatic bacteremia should be deferred.
CB was tested after collection as well as after processing which 
allowed to detect contamination related to inadequate disinfection 
of the umbilical cord or failure to observe microbiological purity 
standards during collection. No bacterial growth was found in three 
samples collected after processing; the same component was found 
contaminated just after collection. This might be due to the bactericidal 
effect of DMSO or small amount of bacteria in product. Similar results 
were reported by Padley et al. for components repeatedly tested after 
thawing [1].
In one of our study samples, two different bacterial species 
were identified before (Leuconostoc spp.) and after processing 
(Staphylococcus capitis). This may be the result of the small number 
of bacteria in the sample or their uneven concentration and distribution 
in the product.
Our analysis demonstrates the need for implementation of 
bacteriological monitoring of components immediately after collection 
as well as after processing; in 2015, this requirement was implemented 
for all HSC products. This procedure revealed that bacterial 
contamination found in all three components had most probably 
occurred in the processing period. At the same time, it is likely that a 
small number of bacteria in the product immediately after collection 
may give false-negative results in the test sample.
Moreover, bacteriological analysis demonstrated that this may have 
occurred as superinfection during sampling, the more so that the 
whole processing procedure was performed in a closed system. Since 
sampling is not performed within a closed system, it may be identified 
as the critical step of activity. It is therefore reasonable to consider a 
change of sampling technique, for example, transfer of drain segments 
to a microbiological laboratory for direct media inoculation to ensure 
adequate quality of the sample.
The results of our study demonstrate that the bacterial contamination 
rate at IHTM is relatively low. Of crucial importance here are internal 
audits as well as constant monitoring of all activities. At the same time, 
we may see that processing in a closed system is not as crucial as might 
be expected. This is particularly true for BM components. Similar results 
are reported by Cassens et al. who found no significant impact of the 
processing environment on bacterial contamination rate. The authors 
compared the bacterial contamination rate during cell processing in a 
laminar air flow chamber subjected to systematic microbiological control 
located in a B class clean room with that for laminar air flow chamber 
inspected only once a year and located in a no-class room [8].
Cell processing is most commonly performed in clean rooms according 
to Good Manufacturing Practice (GMP). Alternatively, the processing 
may take place in a closed system which reduces high maintenance 
costs of such clean rooms [24, 25].
Bacterial contamination implies the loss of transplantation material. As 
mentioned earlier, the IHTM policy permits no bacteria-contaminated 
components for clinical use. Extremely dangerous for the recipient is 
transplantation of components bacteria-contaminated directly after 
collection when results of culture tests are still unavailable. However, 
cryopreservation and cryoprotectants may also contribute to bacterial 
viability; the bacteria remaining in the contaminated product may grow 
after the product is thawed and infused to the recipient [18].
Our study results identify staff experience as crucial for prevention 
of HSC contamination. After the initial 3-year period (1996–1998) 
when HSC components were found bacteria-contaminated, no 
contaminations were reported for several consecutive years. Increase 
in contamination rate was reported during the next several years most 
likely as outcome of liberal approach of staff to the routinely performed 
activities. In 2010, an increase in the number of contaminated 
autologous components was reported most likely due to liberalization 
of the approach to the health of autologous donors and the use of 
vascular catheters. More attention was therefore directed to donor 
health and processing procedures in the years that followed.
Staff overload is another risk factor; the same number of people has 
to prepare a growing number of HSC components. Until 2012, no 
significant changes have been introduced as regards performance at 
each step of the preparation process.
Implementation of a closed system should have completely eliminated 
contamination during the preparation process. It follows therefore that 
the sample collecting procedure requires change to avoid superinfection 
and acquisition of appropriate information on bacteriological safety of 
the component. At stake here is prevention of unwarranted deferral of 
components from clinical use.
We conclude from our study that careful attention should be paid to 
the puncture site from which source material is collected. Apart from 
using the closed system during preparation, components should be 
investigated for contamination directly after HSC collection as well as 
after processing. The use of an appropriate method and technique for 
sample collection is of utmost priority.
Acknowledgment
The authors would like to thank Ms Krystyna Dudziak for her 
contribution and assistance.
A c t a  H a e m a t o l o g i c a  P o l o n i c a
33
Authors’ contributions
JA-P – conceived the idea for the study and was responsible for 
research design, interpretation of results and preparing of the 
manuscript. EL, AR – were responsible for data collection. MŁ – was 
responsible for the final review of the manuscript.
Conflict of interest
The authors have no conflicts of interest to declare.
 
Financial support
Research supported by the Institute of Hematology and Transfusion 
Medicine (IHTM), Warsaw, Poland.
Ethics
The work described in this article has been carried out in accordance 
with The Code of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans; EU Directive 2010/63/ 
EU for animal experiments; Uniform requirements for manuscripts 
submitted to biomedical journals.
[1] Padley DJ, Dietz AB, Gastineau DA. Sterility testing of hematopietic 
progenitur cell products: a single-institution series of culture-
positive rates and successful infusion of culture-positive products. 
Transfusion 2007;47:636–43.
[2] Kelly M, Roy DC, Labbe AC, Laverdiere M. What is the clinical 
significance of infusing hematopoietic cell grafts contaminated 
with bacteria? Bone Marrow Transplant 2006;38:183–88.
[3] Domanović D, Cassini A, Bekeredjian-Ding I, et al. Prioritizing of 
bacterial infections transmitted through substances of human 
origin in Europe. Transfusion 2017;57:1311–17.
[4] Störmer M, Wood EM, Schurig U, et al. Bacterial safety of cell-based 
therapeutic preprations, focusing on haematopietic progenitor 
cells. Vox Sang 2014;106:285–96.
[5] Directive 2004/23/EC of The European Parliament and of The 
Council of 31 March 2004 on setting standards of quality and safety for 
the donation, procurement, testing, processing, preservation, storage 
and distribution of human tissues and cells. OJ L 102, 7.4.2004, p.48.
[6] 3rd Edition of the Guide to the quality and safety of tissues and cells 
for human application. EDQM, Council of Europe, 2017.
[7] Wuchter P. Processing, cryopreserving and controlling the quality 
of HSCs. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT 
Handbook. Hematopoietic Stem Cell Transplantation and Cellular 
Therapies. Cham: Springer; 2019, pp. 127-30.
[8] Cassens U, Ahlke C, Garritsen H, et al. Processing of peripheral 
blood progenitor cell components in improved clean areas does 
not reduce the rate of microbial contamination. Transfusion 
2002;42:10–17.
[9] Husebekk A,  Skaug K,  Kolstad A,  Dahl IM,  Gutteberg T,  Skogen B. 
Hepatitis B virus-infected peripheral blood progenitor cel harvests 
in liquid nitrogen frezer containing non-infectious products. 
Transfusion 2004;44:942–3.
[10] Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers: a 
potential source of microbial contamination of hematopoietic stem 
cell components. Transfusion 1997;37:585–91.
[11] Mastronardi C,  Yang L,  Halpenny M,  Toye B,  Ramírez-Arcos S. 
Evaluation of the sterility testing process of hematopoietic stem 
cells at Canadian Blood Services. Transfusion 2012;52:1778–84.
[12] Arlt N, Rothe R, Juretzek T, Peltroche H, Tonn T, Moog R. Detection 
of the relatively slow-growing Priopionibacterium acnes in seven 
matrices of blood components and advanced therapeutical 
medicinal products. Transf Aph Sci 2017;56:461–65.
[13] Kamble R, Pant S, Selby GB, et al. Microbial contamination of 
hematopoietic progenitor cell grafts-incidence, clinical outcome, and 
cost-effectiveness: an analysis of 735 grafts. Transfusion 2005;45:874–8.
[14] Patah PA, Parmar S, McMannis J, et al. Microbial contamination of 
hematopoietic progenitor cell products: clinical outcome. Bone 
Marrow Transplant 2007;40:365–8.
[15] Dal MS, Tekgűndűz E, Cakar MK, et al. Does microbial contamination 
influence the success of the hematopoietic cell transplantation 
outcomes? Transf Apher Sci 2016;55:125–8.
[16] Donmez A, Aydemir S, Arik B, et al. Risk factors for microbial 
contamination of peripheral blood stem cell products. Transfusion 
2012;52:777–81.
[17] Namdaroğlu S, Tekgűndűz E, Bozdağ SC, et al. Microbial contamination 
of hematopoietic progenitor cell products. Transf and Aph Sci 
2013;48:403–6.
[18] Clark P, Trickett A, Saffo S, Stark D. Effects of cryopreservation on 
microbial-contaminated cord blood. Transfusion 2014;54:532–40.
[19] Girard M, Laforce-Lavoie A, Joële de Grandmont M, et al. Optimization 
of cord blood unit sterility testing: impact of dilution, analysis delay, 
and inhibitory substances. Transfusion 2017;57:1956–67.
[20] Vanneaux V, Foȉs E, Robin M, et al. Microbial contamination of BM 
products before and after processing: a report of incidence and 
immediate adverse events in 257 grafts. Cytotherapy 2007;9:508–13.
[21] Klein MA, Kadidlo D, McCullough J, McKenna DH, Burns LJ. Microbial 
contamination of hematopoietic stem cell products: incidence and 
clinical sequelae. Biol Blood Marrow Transplant 2006;12:1142–9.
[22] Almeida ID, Schmalfuss T, Röhsig LM, Goldani LZ. Autologous 
transplant: microbial contamination of hematopoietic stem cell 
products. Braz J Infect Dis 2012;16:345–50.
[23] Kozłowska-Skrzypczak M, Bembnista E, Kubiak A, Matuszak P, Schneider 
A, Komarnicki M. Microbial contamination of peripheral blood and 
bone Marrow hematopoietic cell products and environmental 
contamination in a stem cell bank: a single-center report. Transplant 
Proceed 2014;46:2873–6.
[24] Spoerl S, Peter R, Krackhardt AM. Cryopreservation in closed bag 
systems as an alternative to clean rooms for preparations of peripheral 
blood stem cells.  Adv Exp Med Biol 2016;951:67–76.
[25] Humpe A, Jansen P, Tischer BK, et al. Cryopreservation of cellular 
products in a closed-bag system with an incorporated dimethyl 
sulfoxide-resistant sterile filter outside of cleanroom facilities. 
Transfusion 2007;47:1033–41.
References
